Voyager Therapeutics Inc
VYGR
NASDAQ
Biotechnology
$3.27
USD
+0.05 (+1.55%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $193.35M
Volume 305.9K
Revenue
$34.46M
TTM
-19.1%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-107.73M
TTM
+0.2%
YoY
Operating Cash Flow
$-120.57M
TTM
-6.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 5.2 | 13.4 | 15.3 | 2.6 | 3.2 |
YoY Growth | -82.4% | -45.7% | +144.3% | -59.9% | -39.1% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 5.2 | 13.4 | 15.3 | 2.6 | 3.2 |
Selling, General & Administrative | 10.5 | 8.1 | 9.3 | 8.3 | 7.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 41.8 | 44.0 | 45.3 | 32.9 | 29.6 |
Operating Income | -36.6 | -30.6 | -29.9 | -30.3 | -26.4 |
EBITDA | -35.6 | -29.7 | -28.9 | -29.3 | -25.5 |
Other Income / Expense | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
Total Other Income / Expense | 3.3 | 2.8 | 2.5 | 2.3 | 1.9 |
Income Before Income Taxes | -33.4 | -27.8 | -27.4 | -27.9 | -24.5 |
Income Taxes | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Net Income | -33.4 | -27.9 | -27.4 | -27.9 | -24.5 |
Consolidated Net Income / Loss | -33.4 | -27.9 | -27.4 | -27.9 | -24.5 |
Net Income Attributable to Common Shareholders | -33.4 | -27.9 | -27.4 | -28.2 | -24.5 |
Basic EPS | -$0.57 | -$0.47 | -$0.47 | -$0.47 | -$0.40 |
Diluted EPS | -$0.57 | -$0.47 | -$0.47 | -$0.47 | -$0.40 |
Basic Shares Outstanding | 58.7M | 58.8M | 58.9M | 59.5M | 60.5M |
Diluted Shares Outstanding | 58.7M | 58.8M | 58.9M | 59.5M | 60.5M |